Published in Virus Res on June 22, 2013
Viral Therapy in Treating Patient With Liver Cancer | NCT01628640
Interferon-γ Inhibits Ebola Virus Infection. PLoS Pathog (2015) 0.85
Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1. Virology (2015) 0.79
Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection. Vet Res (2014) 0.79
Genome rearrangement affects RNA virus adaptability on prostate cancer cells. Front Genet (2015) 0.78
Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS. Hum Gene Ther Clin Dev (2016) 0.78
Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus. Virology (2014) 0.77
A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice. PLoS One (2014) 0.77
Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. ILAR J (2016) 0.77
The Antiviral RNA Interference Response Provides Resistance to Lethal Arbovirus Infection and Vertical Transmission in Caenorhabditis elegans. Curr Biol (2017) 0.77
Interferon regulatory factor 2 protects mice from lethal viral neuroinvasion. J Exp Med (2016) 0.75
Ruxolitinib and polycation combination treatment overcomes multiple mechanisms of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. J Virol (2017) 0.75
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature (2001) 25.15
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature (2006) 22.65
Functional role of type I and type II interferons in antiviral defense. Science (1994) 18.92
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science (2004) 16.26
5'-Triphosphate RNA is the ligand for RIG-I. Science (2006) 15.78
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 14.80
Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell (1996) 10.44
Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08
Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A (2004) 9.00
Type I interferons in host defense. Immunity (2006) 7.32
Defective viral particles and viral disease processes. Nature (1970) 7.24
Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci U S A (1995) 6.95
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science (1988) 5.56
Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. Nature (2005) 5.30
Pathway of vesicular stomatitis virus entry leading to infection. J Mol Biol (1982) 5.21
Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature (2003) 4.80
IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog (2008) 4.70
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med (2000) 4.37
Immune function of astrocytes. Glia (2001) 4.05
A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding. J Virol (1999) 3.92
The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol (1996) 3.89
Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci U S A (2005) 3.74
RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell (2010) 3.59
L protein requirement for in vitro RNA synthesis by vesicular stomatitis virus. J Virol (1973) 3.26
Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J Virol (1990) 3.11
Endosome-to-cytosol transport of viral nucleocapsids. Nat Cell Biol (2005) 2.98
Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol (2010) 2.98
Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon. J Virol (2005) 2.90
Does Toll-like receptor 3 play a biological role in virus infections? Virology (2004) 2.73
Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction. J Virol (2001) 2.66
Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol (2008) 2.62
Vesicular stomatitis virus enters cells through vesicles incompletely coated with clathrin that depend upon actin for internalization. PLoS Pathog (2009) 2.59
VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell (2005) 2.55
The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol (1999) 2.46
Tubulin: a factor necessary for the synthesis of both Sendai virus and vesicular stomatitis virus RNAs. Proc Natl Acad Sci U S A (1986) 2.45
Folding of VSV G protein: sequential interaction with BiP and calnexin. Science (1994) 2.45
Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol (2002) 2.44
Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med (2004) 2.42
Direct method for quantitation of extreme polymerase error frequencies at selected single base sites in viral RNA. J Virol (1986) 2.41
IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog (2010) 2.39
Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol (2001) 2.38
Ars2 regulates both miRNA- and siRNA- dependent silencing and suppresses RNA virus infection in Drosophila. Cell (2009) 2.38
Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol Cell (2000) 2.33
ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Mol Cell Biol (2005) 2.31
Lack of evolutionary stasis during alternating replication of an arbovirus in insect and mammalian cells. J Mol Biol (1999) 2.28
Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells. Virology (2005) 2.24
Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site? Cell (1983) 2.11
Viral proteins required for the in vitro replication of vesicular stomatitis virus defective interfering particle genome RNA. Virology (1988) 2.11
Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol (2003) 2.10
The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J Virol (2000) 2.08
High nucleotide substitution error frequencies in clonal pools of vesicular stomatitis virus. J Virol (1989) 2.04
Phosphorylation by cellular casein kinase II is essential for transcriptional activity of vesicular stomatitis virus phosphoprotein P. Proc Natl Acad Sci U S A (1992) 2.03
Unconventional mechanism of mRNA capping by the RNA-dependent RNA polymerase of vesicular stomatitis virus. Mol Cell (2007) 2.03
Neurons produce type I interferon during viral encephalitis. Proc Natl Acad Sci U S A (2006) 2.02
Inverted complementary terminal sequences in single-stranded RNAs and snap-back RNAs from vesicular stomatitis defective interfering particles. J Gen Virol (1978) 2.02
Cost of host radiation in an RNA virus. Genetics (2000) 1.95
Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. Virology (2007) 1.94
Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell (2004) 1.93
Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol (2001) 1.92
Complex formation with vesicular stomatitis virus phosphoprotein NS prevents binding of nucleocapsid protein N to nonspecific RNA. J Virol (1988) 1.91
Cryo-EM model of the bullet-shaped vesicular stomatitis virus. Science (2010) 1.90
Establishment of cell lines persistently infected with foot-and-mouth disease virus. Virology (1985) 1.84
Interferon-induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis. PLoS Pathog (2012) 1.84
Extreme fitness differences in mammalian and insect hosts after continuous replication of vesicular stomatitis virus in sandfly cells. J Virol (1995) 1.84
Host cell factors and functions involved in vesicular stomatitis virus entry. J Virol (2008) 1.83
Structure of the vesicular stomatitis virus nucleocapsid in complex with the nucleocapsid-binding domain of the small polymerase cofactor, P. Proc Natl Acad Sci U S A (2009) 1.78
Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1. J Virol (2002) 1.78
Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem (1997) 1.76
LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A (2013) 1.75
IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res (2005) 1.75
Inhibition of vesicular stomatitis virus mRNA synthesis by human MxA protein. J Virol (1991) 1.74
Two RNA polymerase complexes from vesicular stomatitis virus-infected cells that carry out transcription and replication of genome RNA. Proc Natl Acad Sci U S A (2004) 1.74
Transcriptional activity and mutational analysis of recombinant vesicular stomatitis virus RNA polymerase. J Virol (1993) 1.73
Vesicular stomatitis. Vet J (1999) 1.73
Factors involved in the generation and replication of rhabdovirus defective T particles. J Virol (1976) 1.72
Vesicular stomatitis virus as an oncolytic vector. Viral Immunol (2004) 1.70
The role of vesicular stomatitis virus matrix protein in inhibition of host-directed gene expression is genetically separable from its function in virus assembly. J Virol (1993) 1.70
Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J Virol (2001) 1.70
Amino acid residues within conserved domain VI of the vesicular stomatitis virus large polymerase protein essential for mRNA cap methyltransferase activity. J Virol (2005) 1.69
Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology (2006) 1.66
Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J Virol (2004) 1.66
Structures of vesicular stomatitis virus glycoprotein: membrane fusion revisited. Cell Mol Life Sci (2008) 1.63
Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol (2011) 1.61
Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice. J Virol (1995) 1.60
A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther (2008) 1.60
A conserved motif in region v of the large polymerase proteins of nonsegmented negative-sense RNA viruses that is essential for mRNA capping. J Virol (2007) 1.57
Local type I IFN receptor signaling protects against virus spread within the central nervous system. J Immunol (2009) 1.57
Virus-induced interference in heterologously infected HeLa cells. J Virol (1972) 1.57
The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis. Glia (1995) 1.55
Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther (2009) 1.54
Visualization of intracellular transport of vesicular stomatitis virus nucleocapsids in living cells. J Virol (2006) 1.53
Nonsegmented negative-strand viruses as vaccine vectors. J Virol (2006) 1.53
Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J Virol (1995) 1.52
In vitro synthesis of messenger RNA by a defective interfering particle of vesicular stomatitis virus. Proc Natl Acad Sci U S A (1977) 1.51
Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther (2010) 1.51
A host protein (La) binds to a unique species of minus-sense leader RNA during replication of vesicular stomatitis virus. Proc Natl Acad Sci U S A (1983) 1.50
Chemical control of phospholipid distribution across bilayer membranes. Med Res Rev (2002) 1.49
Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp Neurol (1998) 1.49
Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol (2002) 1.49
Systematic, genome-wide identification of host genes affecting replication of a positive-strand RNA virus. Proc Natl Acad Sci U S A (2003) 2.43
Cultured astrocytes express toll-like receptors for bacterial products. Glia (2003) 2.01
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol (2012) 1.34
Sex differences in the vaccine-specific and non-targeted effects of vaccines. Vaccine (2011) 1.27
Magic angle spinning solid-state NMR spectroscopy for structural studies of protein interfaces. resonance assignments of differentially enriched Escherichia coli thioredoxin reassembled by fragment complementation. J Am Chem Soc (2004) 1.21
Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity. Biol Reprod (2007) 1.18
Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi. J Immunol (2008) 1.13
The role of Toll-like receptors in CNS response to microbial challenge. J Neurochem (2006) 1.12
Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology (2012) 1.12
Resonance assignments and secondary structure analysis of E. coli thioredoxin by magic angle spinning solid-state NMR spectroscopy. J Phys Chem B (2005) 1.08
Functional expression of NOD2, a novel pattern recognition receptor for bacterial motifs, in primary murine astrocytes. Glia (2006) 1.08
Expression of functional NK-1 receptors in murine microglia. Glia (2002) 1.05
NOD2 plays an important role in the inflammatory responses of microglia and astrocytes to bacterial CNS pathogens. Glia (2009) 1.05
Borrelia burgdorferi induces inflammatory mediator production by murine microglia. J Neuroimmunol (2002) 1.04
Estrogens augment cell surface TLR4 expression on murine macrophages and regulate sepsis susceptibility in vivo. Endocrinology (2009) 1.04
Murine glia express the immunosuppressive cytokine, interleukin-10, following exposure to Borrelia burgdorferi or Neisseria meningitidis. Glia (2006) 1.04
Characterization of nucleotide-binding oligomerization domain (NOD) protein expression in primary murine microglia. J Neuroimmunol (2006) 1.01
Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol (2012) 1.01
A role for DNA-dependent activator of interferon regulatory factor in the recognition of herpes simplex virus type 1 by glial cells. J Neuroinflammation (2011) 1.00
Staphylococcus aureus - induced tumor necrosis factor - related apoptosis - inducing ligand expression mediates apoptosis and caspase-8 activation in infected osteoblasts. BMC Microbiol (2003) 1.00
Substance P augments Borrelia burgdorferi-induced prostaglandin E2 production by murine microglia. J Immunol (2004) 1.00
Bacterium-induced CXCL10 secretion by osteoblasts can be mediated in part through toll-like receptor 4. Infect Immun (2002) 1.00
NOD2 mediates inflammatory responses of primary murine glia to Streptococcus pneumoniae. Glia (2010) 0.99
Vesicular stomatitis virus infects resident cells of the central nervous system and induces replication-dependent inflammatory responses. Virology (2010) 0.97
Staphylococcus aureus induces expression of receptor activator of NF-kappaB ligand and prostaglandin E2 in infected murine osteoblasts. Infect Immun (2008) 0.96
Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin. PLoS One (2010) 0.95
Osteoblasts express NLRP3, a nucleotide-binding domain and leucine-rich repeat region containing receptor implicated in bacterially induced cell death. J Bone Miner Res (2008) 0.95
Viral CNS infections: role of glial pattern recognition receptors in neuroinflammation. Front Microbiol (2012) 0.95
Functional CD40 expression induced following bacterial infection of mouse and human osteoblasts. Infect Immun (2003) 0.94
Magic angle spinning NMR spectroscopy of thioredoxin reassemblies. Magn Reson Chem (2007) 0.94
The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. J Surg Oncol (2013) 0.94
RIG-I mediates nonsegmented negative-sense RNA virus-induced inflammatory immune responses of primary human astrocytes. Glia (2010) 0.93
Characterization of retinoic acid-inducible gene-I expression in primary murine glia following exposure to vesicular stomatitis virus. J Neurovirol (2008) 0.92
Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis. J Immunol (2011) 0.92
Murine gamma-herpesvirus 68 limits naturally occurring CD4+CD25+ T regulatory cell activity following infection. J Immunol (2006) 0.91
GPR30/GPER-1 mediates rapid decreases in TLR4 expression on murine macrophages. Mol Cell Endocrinol (2010) 0.89
Expression of hemokinin 1 mRNA by murine dendritic cells. J Neuroimmunol (2004) 0.89
Bacterial infection induces expression of functional MHC class II molecules in murine and human osteoblasts. Bone (2003) 0.88
Murine gammaherpesvirus-68 elicits robust levels of interleukin-12 p40, but not interleukin-12 p70 production, by murine microglia and astrocytes. J Neurovirol (2004) 0.87
pH dependence of amide chemical shifts in natively disordered polypeptides detects medium-range interactions with ionizable residues. Biophys J (2005) 0.87
Signaling via Toll-like receptor 5 can initiate inflammatory mediator production by murine osteoblasts. Infect Immun (2003) 0.86
Analysis of virion associated host proteins in vesicular stomatitis virus using a proteomics approach. Virol J (2009) 0.86
Causative agents of osteomyelitis induce death domain-containing TNF-related apoptosis-inducing ligand receptor expression on osteoblasts. Bone (2010) 0.85
NOD2 contributes to the inflammatory responses of primary murine microglia and astrocytes to Staphylococcus aureus. Neurosci Lett (2010) 0.84
Astrocytes produce IL-19 in response to bacterial challenge and are sensitive to the immunosuppressive effects of this IL-10 family member. Glia (2014) 0.84
Identification of sendai virus L protein amino acid residues affecting viral mRNA cap methylation. J Virol (2008) 0.83
Differential roles for NOD2 in osteoblast inflammatory immune responses to bacterial pathogens of bone tissue. J Med Microbiol (2010) 0.83
Reduced CTL response and increased viral burden in substance P receptor-deficient mice infected with murine gamma-herpesvirus 68. J Immunol (2003) 0.81
Reversal of negative charges on the surface of Escherichia coli thioredoxin: pockets versus protrusions. Biochemistry (2004) 0.81
Tissue engineering scaffold for sequential release of vancomycin and rhBMP2 to treat bone infections. J Biomed Mater Res A (2014) 0.80
Early osteoblast responses to orthopedic implants: Synergy of surface roughness and chemistry of bioactive ceramic coating. J Biomed Mater Res A (2014) 0.80
Murine gammaherpesvirus-68 infects microglia and induces high levels of pro-inflammatory cytokine production. J Neuroimmunol (2003) 0.79
Sequence-function analysis of the Sendai virus L protein domain VI. Virology (2010) 0.79
Alpha beta-crystallin expression and presentation following infection with murine gammaherpesvirus 68. Autoimmunity (2013) 0.78
Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma. J Virol (2013) 0.77
Detecting protein-protein interactions in vesicular stomatitis virus using a cytoplasmic yeast two hybrid system. J Virol Methods (2011) 0.76
Systemic host immuno-inflammatory response to dental extractions and periodontitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2008) 0.75
Promotion of pro-osteogenic responses by a bioactive ceramic coating. J Biomed Mater Res A (2012) 0.75
From the editors. Immunopharmacol Immunotoxicol (2016) 0.75